Mass Spectrometry for Detection of Monoclonal Gammopathy of Undetermined Significance
Researchers compared the monoclonal immunoglobulin rapid accurate measurement and matrix-assisted laser desorption/ionization-time of flight assays.
Multiple Myeloma News
MULTIPLE MYELOMA ADVISOR
Multiple Myeloma News
Belantamab Mafodotin Gets Priority Review for Heavily Pretreated Multiple Myeloma
The FDA has granted Priority Review to the Biologics License Application (BLA) of belantamab mafodotin (GSK2857916; GlaxoSmithKline) for the treatment of patients with relapsed or refractory multiple myeloma whose prior therapy included an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody.
Comparison of Treatment With Bortezomib and Lenalidomide for Relapsed Multiple Myeloma
Progression-free survival, overall survival, and percentage of patients who achieved very good partial response or better were similar between both treatment groups.
Ruxolitinib Plus PEG-IFNα2 for Patients With Polycythemia Vera or Myelofibrosis
The study’s primary endpoint was efficacy, determined by complete remission, peripheral blood cell count remission, quality of life, and JAK2 V617F allele burden.
Phase 2 Trial of Ibrutinib, Bortezomib, Dexamethasone Combination for R/R Multiple Myeloma Was Closed Early
Despite an overall response rate of 57%, this clinical trial was suspended due to safety concerns then closed early due to insufficient activity of the study drug combination.
Caution Urged When Considering Denosumab in Patients With Multiple Myeloma Who Have Normal Renal Function
Bisphosphonate therapy is associated with renal toxicity.
MRD Status Assessed by Flow Cytometry Predicts Treatment Efficacy in Newly Diagnosed Multiple Myeloma
Next-generation flow cytometry involves assessments of both plasma cell-surface antigens and immunoglobulin light-chain expression.
Daratumumab Increased Myeloma Patient Risk for Listeria
Patients with multiple myeloma may want to avoid consumption of foods associated with Listeria.
Inhibiting BCMA Antigen Loss May Enhance BCMA-Directed CAR-T Therapy in R/R MM
A putative mechanism of resistance to BCMA-directed CAR-T therapy involves BCMA antigen loss through cleavage of BCMA from the surface of myeloma cells.
Epigenetic Drug CPI-0610 Called Clinically Active, Tolerable in Myelofibrosis
“Among evaluable patients who were transfusion dependent on ruxolitinib, 6 of 14 patients converted to transfusion independence after the addition of CPI-0610.”
Long-Term Follow-Up of BCMA-Directed CAR-T in R/R MM: CRs Appear Durable in LEGEND-2
Long-term follow-up from the clinical trial investigating LCAR-B38M, a BCMA-targeting CAR-T, revealed that approximately three-quarters of patients achieved a complete response.
More Evidence Supporting the Benefit of Anti-BCMA CAR-T in R/R Multiple Myeloma: The CARTITUDE Study
JNJ-4528 is a CAR-T therapy in which 2 antibodies against the B-cell maturation antigen BCMA are expressed on T cells.
Evidence of Clinical Benefit for Bispecific Antibody in Patients With Refractory Multiple Myeloma
This dose-finding study examined a bispecific antibody targeting BCMA and CD3 in patients with R/R multiple myeloma.
Circulating Tumor Plasma Cells Predict Progression in Myeloma
The presence of circulating tumor plasma cells by next-generation flow independently predicted disease progression after treatment in patients with multiple myeloma.
Chromosomal Aberrations in Clones Seem Prognostic in Smoldering Myeloma
The detection of chromosomal aberrations in the main clone appear to have prognostic significance in patients with smoldering myeloma.
MPN-Directed Therapy Does Not Alter Timing of Clinical Manifestations of Splanchnic Vein Thrombosis
A retrospective analysis sought to determine the association between myeloproliferative neoplasms, MPN-directed therapy, and development of splanchnic vein thrombosis.
Antibiotic Prophylaxis Reduced Febrile Episodes, Death in Newly Diagnosed Myeloma in TEAMM Trial
The TEAMM trial sought to assess time to first febrile episode or death from all causes in patients with newly diagnosed myeloma who received antibiotic prophylaxis vs those who did not.
Potential Link Between Tumor Necrosis Factor-α and Peripheral Neuropathy Observed With Bortezomib Treatment in Multiple Myeloma
Researchers explored a possible link between TNF-α and peripheral neuropathy in patients with MM treated with bortezomib.
Outcomes With Plerixafor Following Autologous Stem Cell Transplantation for Multiple Myeloma
The addition of plerixafor to treatment following transplantation may not enhance lymphocyte recovery in patients with multiple myeloma.
Exploring High Levels of Uncertainty Regarding HCT in Myeloma, Lymphoma, Leukemia
Uncertainty is defined in this study as “the inability to give sense or meaning to the processes or situations that have to do with medical conditions.”
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma News
